Director/PDMR Shareholding

RNS Number : 0556F
Advanced Medical Solutions Grp PLC
18 April 2011

For Release: 18 April 2011

Advanced Medical Solutions Group plc

(“AMS” or the “Company”)


Directors’ shareholdings


Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, announces that the Board, following a recommendation from the Remuneration Committee, has granted new share options to the following Directors under the Advanced Medical Solutions Long Term Incentive Plan (the ‘LTIP’) on 15 April 2011.  The vesting of these options is subject to certain performance criteria over a three year period.




Options prior to grant

Options granted

Resultant holding

Chris Meredith, Chief Executive Officer




Mary Tavener, Group Finance Director





– Ends –


For further information, please visit or contact:


Advanced Medical Solutions Group plc

Tel: +44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Mary Tavener, Group Finance Director

Tavistock Communications

Tel: +44 (0) 207 920 3150

John West / Chris Munden / Andrew Dunn / Lydia Eades

Investec Bank plc

Tel: +44 (0) 207 597 5970

Gary Clarence / Daniel Adams / Patrick Robb


Notes to Editors:


AMS’ advanced woundcare products are based on an extensive range of technologies including alginates, silver alginates and hydrophilic polyurethane foams. These and other products pioneer the concept of moist wound healing, allowing wounds to heal faster and with less pain and scarring. They protect the wound, deal with tissue fluids and provide an optimal environment for healing to occur. Silver is widely recognised as a safe and effective broad-spectrum anti-microbial agent for infection control.


AMS’ wound closure and sealants products are based on cyanoacrylate adhesive (“superglue”) technology developed for medical applications. Tissue adhesives offer significant benefits over conventional ways of closing wounds following trauma or surgical incision. They are simple to use, non-invasive, help to reduce the risk of infection, minimise trauma to the patient and provide good clinical and cosmetic outcomes. The technology is also ideally suited to protecting skin from breakdown or for use as a skin sealant to help prevent infection of surgical sites.

This information is provided by RNS
The company news service from the London Stock Exchange